| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Asp-NH2 is used as a protected amino acid in peptide synthesis, targeting the formation of peptide bonds. The Fmoc group protects the α-amino group, preventing unwanted side reactions during chain elongation. The side-chain amide (asparagine-like) serves as a protecting group for the β-carboxyl of aspartic acid, preventing side-chain condensation. This building block is incorporated into synthetic peptides for applications in medicinal chemistry, drug discovery, and antibody generation. It is a reagent, not a bioactive compound itself.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro, Fmoc-Asp-NH2 is utilized in SPPS to synthesize peptides for various biological assays. The resulting peptides may include aspartic acid in their sequence, which can be important for enzyme recognition or metal chelation. The compound's purity is critical; it is typically assayed by HPLC and MS. The final peptides are used in receptor binding, enzyme inhibition, and cell-based assays to study protein function and drug targets. The compound itself does not have a direct biological activity but enables the production of active peptides. |
| ln Vivo |
In vivo, Fmoc-Asp-NH2 is not administered directly; its relevance is in the final peptides synthesized. These peptides may be developed as therapeutic agents or vaccines, and their in vivo activity depends on the sequence and structure. The compound is a research reagent, and its safety is evaluated for handling in the laboratory, not for in vivo application.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed with Fmoc-Asp-NH2 itself, as it is a synthetic intermediate. However, the peptides synthesized from it are often characterized by binding assays. The compound's purity is assessed by HPLC and LC-MS to ensure the integrity of the building block before use. Functional assays for the final products, such as receptor binding or enzyme inhibition, are conducted according to the target of interest.
|
| Cell Assay |
In vitro cellular experiments are not conducted with Fmoc-Asp-NH2. It is used exclusively in chemical synthesis. The final peptides may be tested in cell-based assays for bioactivity, but this is beyond the scope of this building block. Cell viability, cytotoxicity, and functional assays are performed on the final peptide products, not on the amino acid derivative.
|
| Animal Protocol |
In vivo animal studies are not applicable to Fmoc-Asp-NH2. The peptides synthesized from it may be evaluated in vivo, but the building block itself is not administered. The compound is a research reagent, and its toxicology is not studied beyond standard chemical safety data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Fmoc-Asp-NH2, as it is not a drug. It is a chemical intermediate; its stability and handling are the primary concerns. For the final peptide products, pharmacokinetics would be determined separately.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Fmoc-Asp-NH2 is limited to its chemical safety. It is not used in living systems; only standard laboratory precautions are required. The compound is not classified as hazardous, but it should be handled with gloves and eye protection. No specific toxicological data are available, as it is not intended for human exposure.
|
| Additional Infomation |
Fmoc-Asp-NH2 is a key building block in peptide synthesis, specifically for incorporating aspartic acid residues. Its Fmoc protection allows for facile deprotection, and the side-chain amide protects the β-carboxyl group, enabling the synthesis of complex peptides. It is widely used in medicinal chemistry and drug discovery to generate peptide libraries for screening. This compound is a research reagent and is not a therapeutic agent.
|
| Molecular Formula |
C₁₉H₁₈N₂O₅
|
|---|---|
| Molecular Weight |
354.36
|
| Exact Mass |
354.122
|
| CAS # |
200335-40-6
|
| PubChem CID |
7015831
|
| Appearance |
White to off-white solid powder
|
| Density |
1.362g/cm3
|
| Boiling Point |
662.1ºC at 760 mmHg
|
| Flash Point |
354.2ºC
|
| Vapour Pressure |
1.97E-18mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
2.944
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
26
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)N[C@@H](CC(=O)O)C(=O)N
|
| InChi Key |
VHRMWRHTRSQVJJ-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C19H18N2O5/c20-18(24)16(9-17(22)23)21-19(25)26-10-15-13-7-3-1-5-11(13)12-6-2-4-8-14(12)15/h1-8,15-16H,9-10H2,(H2,20,24)(H,21,25)(H,22,23)/t16-/m0/s1
|
| Chemical Name |
(3S)-4-amino-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid
|
| Synonyms |
FmocAspNH2; Fmoc Asp NH2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8220 mL | 14.1099 mL | 28.2199 mL | |
| 5 mM | 0.5644 mL | 2.8220 mL | 5.6440 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8220 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
